Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Colony-stimulating factors (CSFs) are a class of glycoprotein hormones that stimulate production of the cellular elements of blood. Two of these hormones, granulocyte
macrophage colony-stimulating factor
(GM-CSF) and granulocyte colony-stimulating factor (G-CSF), have shown promise in clinical trials for the treatment of various neutropenic states. This article reviews the published experience in treating patients with GM-
CSF
and G-CSF and points out potential applications of these drugs in clinical practice.
...
PMID:The promise of colony-stimulating factors in clinical practice. 168 43
The cytokine interleukin-1 (IL-1) plays a role in the regulation of normal as well as leukemic hematopoiesis. In acute myeloid leukemia (AML), IL-1 induces autocrine granulocyte/
macrophage colony-stimulating factor
(GM-CSF) and tumor necrosis factor (TNF) production, and these factors may then synergistically induce proliferation in AML blast cells. In this report, we show that IL-1 stimulates DNA synthesis of highly enriched normal bone marrow blast cells (CD34 positive, adherent cell depleted, CD3/CD14/CD15 negative). The stimulative effect of IL-1 can be blocked with neutralizing anti-TNF alpha and anti-GM-CSF antibodies and, most efficiently, by the combination of anti-TNF alpha and anti-GM-CSF, but not with anti-G-CSF antibody, suggesting that IL-1-induced proliferation was initiated through TNF and GM-CSF release. Concentrations of TNF and GM-CSF increased in the culture medium of normal bone marrow blast cells after IL-1 induction. Of the IL-1-induced cells, 12% were positive for GM-
CSF mRNA
by in situ hybridization, as opposed to 6% of non-induced cells. Thus, in addition to its effect on leukemic blast cells, IL-1 also acts on normal marrow blast cells. We propose a scheme where IL-1 stimulation of normal bone marrow blast cells leads to the induction of TNF alpha and GM-CSF, which in association stimulate DNA synthesis efficiently according to a paracrine or autocrine mechanism within the marrow blast cell compartment.
...
PMID:Interleukin-1 alpha also induces granulocyte-macrophage colony-stimulating factor in immature normal bone marrow cells. 169 8
Recombinant murine
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) was noted to support rat bone marrow colony formation in vitro. The in vivo hematologic effects of a single intravenous injection of murine
GM-CSF
were therefore investigated. Doses of murine
GM-CSF
between 0.1 and 5 micrograms/rat caused an increasing leukocytosis that did not further increase with a dose of 25 micrograms/rat. In contrast, human
GM-CSF
at 25 micrograms/rat did not induce any significant peripheral hematologic effects. Murine
GM-CSF
induced peripheral neutrophilia and monocytosis, peaking between 4 and 8 hours and subsiding to baseline by 12 hours. Neutropenia and monocytopenia, which reached a nadir at 15 minutes, preceded the leukocytosis, suggesting that
GM-CSF
activates these leukocytes and causes transient intravascular margination. A mild lymphopenia occurred between 2 to 8 hours. The bone marrow at 6 hours after injection of
GM-CSF
demonstrated a variable and slight left-shifted myeloid hyperplasia most noticeable at the level of promyelocytes and myelocytes, suggesting a myeloproliferative effect. The marrow at 6 hours also demonstrated a decrease in mature neutrophils, documenting that the marrow contributes to the increased number of circulating neutrophils. Once-daily injection of
GM-CSF
for 7 days induced a repetitive daily neutrophilia of the same magnitude. The marrow after 1 week of injections did not show a generalized myeloid hyperplasia, but did show an increase in eosinophils and a decrease in lymphocytes.
Granulocyte-macrophage colony-stimulating factor
plus granulocyte colony-stimulating factor (G-CSF) have been reported to synergize in vitro in both mouse and human bone marrow colony assays. However
GM-CSF
plus G-CSF in vivo, administered as either a single injection or as daily injections for 1 week, were found in the present study to induce, at most, an additive effect on circulating numbers of neutrophils. It is concluded that murine
GM-CSF
will be useful in the rat model to study the in vivo hematoreconstitutive effects of
GM-CSF
alone and in combination with other hematologic growth factors. The relatively rapid kinetics and lesser magnitude of
GM-CSF
-induced neutrophilia and monocytosis, as compared to G-CSF and
M-CSF
, respectively, and the lesser myeloproliferative effect of
GM-CSF
in bone marrow smears, as compared to G-CSF, might be taken to suggest that
GM-CSF
's natural activity is predominantly as an inflammatory rather than a myeloproliferative factor.
...
PMID:Hematologic effects of recombinant murine granulocyte-macrophage colony-stimulating factor on the peripheral blood and bone marrow. 169 84
In order to minimize the interactions of clonogenic cells with accessory cells and characterize the direct effect of recombinant hematopoietic growth factors (HGF) on acute myelogenous leukemia colony-forming cells (AML-CFU), the response of CD34+ AML-CFU to individual or combined recombinant HGF, i.e., interleukin-1 (IL-1), interleukin-3 (IL-3), interleukin-6 (IL-6),
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
), granulocyte colony-stimulating factor (G-CSF), and
macrophage colony-stimulating factor
(
M-CSF
), was studied in 10 patients and compared with the growth response obtained from unfractionated marrow cells. IL-3 and
GM-CSF
had a similar stimulating activity on AML-CFU growth. G-CSF resulted the most efficient stimulus for colony formation and was additive or synergistic with IL-3 and
GM-CSF
,
M-CSF
, used alone, had a negligible stimulating activity. When CD34+ cells were used, IL-1 by itself had a low stimulating activity and displayed little or no synergy with IL-3,
GM-CSF
, and G-CSF. On the contrary, when unfractionated cells were used, IL-1 was very effective in inducing AML-CFU formation and was markedly synergistic with IL-3 and
GM-CSF
. These results show that IL-1-induced leukemic colony formation is prevalently mediated by accessory cells. IL-6 supported AML-CFU growth in seven of 10 cases, thus showing a direct effect on CD34+ leukemic cells, and enhanced the growth of IL-3-(+47 to +167%) and
GM-CSF
-dependent (+60 to +110%) AML-CFU. Recloning studies of single colonies demonstrated that primary CD34+ AML-CFU, stimulated by IL-3 and
GM-CSF
, generated secondary and tertiary colonies, whereas primary AML-CFU stimulated by G-CSF and IL-6 failed to give rise to secondary colonies, thus indicating a complete suppression of self-renewal. Sequential recloning of colonies grown in the presence of IL-3 + IL-6 demonstrated that addition of IL-6 and IL-3-containing plates resulted in a nearly complete suppression of self-renewal. In conclusion, these results demonstrate the heterogeneity of the CD34+ leukemic cell fraction and indicate the existence of complex regulatory events at the level of CD34+ leukemic cells. Data obtained from recloning experiments are of therapeutic interest in view of the clinical application of HGFs in the treatment of myeloid leukemias.
...
PMID:Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors. 169 11
Granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) is a glycoprotein that is required for the survival, growth, and differentiation of hematopoietic progenitor cells. Although the primary structure of
GM-CSF
is known from cDNA cloning, the relationship between structure and function of
GM-CSF
is not fully understood. Fifteen different monoclonal antibodies (MoAbs) to human
GM-CSF
were generated to map immunologically distinct areas of the molecule. Each of the MoAbs was biotinylated and shown by enzyme-linked immunosorbent assay to bind to recombinant
GM-CSF
that had been affixed to a solid phase. Each of the 15 unconjugated MoAbs was then used to compete with each biotinylated MoAb for binding to
GM-CSF
. These cross-blocking studies identified eight distinct epitopes of native
GM-CSF
. Seven of these epitopes were also present in denatured
GM-CSF
by Western blotting, and four of the epitopes were at least partially conserved on
GM-CSF
that was reduced in beta-mercaptoethanol. MoAbs to four of eight epitopes neutralized both recombinant (glycosylated and nonglycosylated) and natural human
GM-CSF
in a GM colony-forming unit (CFU-GM) assay and blocked
GM-CSF
-induced activation of neutrophils. For most of the antibodies there was a good correlation between neutralizing activity and the capacity to block binding of 125I-
GM-CSF
to neutrophils or blasts. Non-neutralizing antibodies to one epitope partially blocked binding of 125I-
GM-CSF
to neutrophils. None of the MoAbs neutralized interleukin-3, G-CSF, or
M-CSF
. The locations of seven of the epitopes could be partially mapped with regard to the amino acid structure by determining reactivity to
GM-CSF
synthetic peptides or to human-mouse chimeric GM-CSFs. The neutralizing antibodies were found to map to amino acids 40-77, 78-94, or 110-127. Thus, these MoAbs are useful to identify functional domains of
GM-CSF
and in identifying regions that are likely to be involved in receptor interaction.
...
PMID:Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. 170 2
The versatility and importance of macrophages in host defense and homeostasis have long been recognized. Anatomically, macrophages isolated from various tissues manifest extreme differences in shape, in metabolic and functional activities, and in the expression of macrophage-specific markers. To determine the mechanisms responsible for generating macrophage heterogeneity, we have employed the reverse transcription-polymerase chain reaction to molecularly phenotype colonies of bone marrow-derived macrophages during differentiation in vitro. By utilizing this method, results have revealed a hierarchal expression of macrophage-associated genes. Tumor necrosis factor alpha was expressed in all colonies analyzed suggesting an important role for this molecule during macrophage differentiation. Predominant colony phenotypes observed were unique for (i) the period of differentiation and (ii) the growth factor with which they were derived (either
colony-stimulating factor 1
or
granulocyte-macrophage colony-stimulating factor
). Exogenous stimulation of the cultures with either bacterial lipopolysaccharide or interferon-gamma led to predictable phenotypic transitions. These results suggest that macrophage heterogeneity is generated through differentiation-related mechanisms and that generated macrophage phenotypes are then maintained by systemic environmental constraints.
...
PMID:Macrophage heterogeneity occurs through a developmental mechanism. 170 15
Hematopoiesis is a complex process that underlines the production of multiple highly specialized cells. The intricate mechanisms involved in this process include both positive and negative feedback by humoral activities, pluripotent stem cell selfrenewal and differentiation, and local interactions between stromal components of the hematopoietic microenvironment and various stem and progenitor cells. A group of hematopoietic growth factors, as well as their genes and chromosomal locations, have been identified. Advances in biochemistry and molecular biology led to the purification, genetic sequencing and molecular cloning of these glycoproteins. They include interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
),
macrophage colony-stimulating factor
(
M-CSF
) and erythropoietin (EPO). The biologic specificity of these substances is defined by their ability to support proliferation and differentiation of hematopoietic cells in a semisolid clonal assay system. These factors share certain characteristics, including their ability to stimulate the function of mature cells, their overlapping activity affecting progenitor cells of several lineages, and their direct and indirect actions on nonhematopoietic cells. Trials using hematopoietic growth factors demonstrated their remarkable efficacy in a variety of clinical settings.
...
PMID:Hematopoietic growth factors. 170 21
Colony-stimulating factors are a family of glycoproteins instrumental in regulation of hematopoiesis and inflammation. Clinical effects of various colony-stimulating factors have been reported in murine and human hosts. This review summarizes findings from some clinical trial evaluations of
macrophage colony-stimulating factor
,
granulocyte-macrophage colony-stimulating factor
, granulocyte colony-stimulating factor, interleukin-1, interleukin-3, interleukin-4, interleukin-5, interleukin-6, and interleukin-7 administration to other species. These factors stimulate clonal expansion of progenitor cells in the bone marrow, induce differentiation of various cell lineages to a mature phenotype, and, in some cases, enhance the effector activities of immune cells. Each colony-stimulating factor has distinct lineages of bone marrow cells upon which they act, although there is some overlap in lineage activity and synergy between colony-stimulating factors. The close relationship in biological activity among different colony-stimulating factors is also reflected at the genomic level at which genes for some hematopoietic growth factors have been mapped to a region of human chromosome 5. Recently, colony-stimulating factor administration to cattle and its potential application to disease control in bovine preventive medicine programs has been investigated. Data from recent hematological, immunological, and intramammary bacterial (Staphylococcus aureus and Klebsiella pneumoniae) challenge studies in dairy cows are reviewed. These studies, with limited numbers of cows, found that rate of new infections, as well as duration and severity of infection, were reduced by pretreatment of cows with granulocyte-colony stimulating factor. The dose-dependent hematological and immunomodulatory effects of granulocyte colony-stimulating factor administration may explain reduced severity and incidence of mastitis in dairy cows given granulocyte colony-stimulating factor.
...
PMID:Immunobiology of hematopoietic colony-stimulating factors: potential application to disease prevention in the bovine. 172 1
Macrophages derived in vitro from bone marrow progenitors (bone marrow-derived macrophages, BMDMs) using either
macrophage colony-stimulating factor
(
CSF-1
) or
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) as the myelopoietic stimulus display differential functional, morphological, and mRNA phenotypes. The data presented here demonstrate further that
CSF-1
- and
GM-CSF
-derived BMDMs differ in immunologic capacity.
GM-CSF
-derived BMDMs, when compared to
CSF-1
-derived BMDMs, showed greater cytolytic activity against tumor necrosis factor alpha (TNF-alpha)-resistant, but not TNF-alpha-sensitive, tumor targets. In contrast,
CSF-1
-derived BMDMs produced nitrite in response to lipopolysaccharide (LPS) alone, whereas
GM-CSF
-derived BMDMs required interferon gamma plus LPS treatment. The two BMDM populations also showed differential sensitivities to LPS for secretion of TNF-alpha and nitrite, but the maximal inducible amounts of these factors and prostaglandin E2 were similar between the BMDM populations. Lastly,
GM-CSF
-derived but not
CSF-1
-derived BMDMs showed an L-arginine-dependent listeriacidal activity. These results show that the functional heterogeneity of
CSF-1
- and
GM-CSF
-derived macrophages is limited and appears to result largely from differences in the activational signals required by each BMDM population to elicit a given function.
...
PMID:Differential immunocompetence of macrophages derived using macrophage or granulocyte-macrophage colony-stimulating factor. 174 Jun 46
There are clones of myeloid leukemic cells that can be induced to undergo terminal cell differentiation to macrophages by normal hemopoietic regulatory proteins. Induction of differentiation in two different clones of myeloid leukemic cells with interleukin 6 (IL-6) or
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) resulted in induction of mRNA for the hemopoietic regulatory proteins IL-6,
GM-CSF
, interleukin 1 alpha and interleukin 1 beta, tumor necrosis factor, and transforming growth factor beta 1. In one of these clones, induction of differentiation with
GM-CSF
was also associated with induction of mRNA for
macrophage colony-stimulating factor
(
M-CSF
) but not for the receptor for
M-CSF
(c-fms), whereas in the other clone, induction of differentiation with IL-6 was associated with induction of mRNA for both c-fms and
M-CSF
. The clones also differed in their responsiveness to these regulators. There was no induction of mRNA for granulocyte colony-stimulating factor or interleukin 3 during differentiation of either clone. The results indicate that the genes for a nearly normal network of positive and negative hemopoietic regulatory proteins are induced during differentiation of these myeloid leukemic cells and that there are leukemic clones with specific defects in this network.
...
PMID:The network of hemopoietic regulatory proteins in myeloid cell differentiation. 175 9
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>